Results 181 to 190 of about 12,173,418 (313)

Impact of Dual Interleukin‐17A and Interleukin‐17F Inhibition With Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: Magnetic Resonance Imaging and Radiographic Outcomes From Two Phase 3 Studies and Their Open‐Label Extension

Arthritis &Rheumatology, EarlyView.
Graphical Abstract Objective To evaluate the impact of bimekizumab, a dual interleukin (IL)‐17A and IL‐17F inhibitor, on sacroiliac joints (SIJ) and spine inflammation/structural damage in axSpA using magnetic resonance imaging (MRI) scans/radiographs from the phase 3 studies BE MOBILE 1 (non‐radiographic axSpA [nr‐axSpA]) and 2 (radiographic axSpA [r ...
Walter P. Maksymowych, Sofia Ramiro, Denis Poddubnyy, Xenofon Baraliakos, Robert G. W. Lambert, Ute Massow, Tom Vaux, Chetan Prajapati, Alexander Marten, Natasha de Peyrecave, Mikkel Østergaard   +10 more
wiley   +1 more source

Placebo, nocebo: Believing in the field of medicine

Frontiers in Pain Research, 2022
Karin Meissner, Karin Meissner
doaj   +1 more source

Mechanisms of open and hidden placebo in stroke recovery: targeting neuroplasticity insights of the placebo effect - study protocol for a controlled, parallel, randomised clinical trial. [PDF]

BMJ Open
Ortega-Márquez J, Camargo L, Gianlorenço AC, Sosa W, Black-Schaffer R, Wang QM, Fregni F.   +6 more
europepmc   +1 more source

Early Diagnosis of Axial Spondyloarthritis Is Associated With Less Long‐Term Spinal Structural Damage: A Longitudinal Analysis of the Swiss Clinical Quality Management in Rheumatic Diseases Registry

Arthritis &Rheumatology, EarlyView.
Objective The Assessment of SpondyloArthritis international Society recently defined early axial spondyloarthritis (axSpA) as a duration of two years or less of axial symptoms. Previous studies have shown no significant difference in short‐term outcomes between patients with early and established axSpA treated with biologic/targeted synthetic disease ...
Annik Steimer, Jonas Brändli, Mauro Bachmann, Andrea Götschi, Claudia L. Rodrigues, Michael J. Nissen, Burkhard Möller, Kristina Bürki, Martin Wendiggensen, Simon Grosswiler, Michael Andor, Diana Dan, Frauke Förger, Sabine Adler, Diego Kyburz, Oliver Distler, Raphael Micheroli, Sofia Ramiro, Adrian Ciurea   +18 more
wiley   +1 more source

The Placebo Effect in Medicine and Clinical Practice: A Narrative Review. [PDF]

Cureus
Tzigkounakis G, Simati K, Georgiadis K.
europepmc   +1 more source

The placebo effect shortens movement time in goal-directed movements. [PDF]

Sci Rep, 2022
Fiorio M, Villa-Sánchez B, Rossignati F, Emadi Andani M.   +3 more
europepmc   +1 more source

Treatment‐Driven Peripheral Blood Transcriptomic Remodeling and Baseline Predictors of ESSDAI and STAR Response to B Cell Therapy in Sjögren's Disease

Arthritis &Rheumatology, EarlyView.
Graphical Abstract Objective This study aimed to characterize whole blood transcriptomic profiles in adults with active Sjögren's disease (SjD) treated with anti‐CD20 or B lymphocyte stimulator/BAFF inhibition, identify markers of clinical response, and define inflammatory pathways linked to nonresponse. Methods Whole blood RNA sequencing was performed
Aimen Ibrahim, Junjie Peng, Eileen Tian, Lucia Martin‐Gutierrez, John Casement, Kyle Thompson, Wan‐Fai Ng, André van Maurik, Elizabeth C. Jury, Coziana Ciurtin   +9 more
wiley   +1 more source

Sustained Inhibition of Structural Damage Progression and Improvements in Disease Activity With Guselkumab in Biologic‐Naïve Participants with Active and Erosive Psoriatic Arthritis: Results Through Week 48 of the Phase 3b Randomized, Double‐Blind, Placebo‐Controlled APEX Study

Arthritis &Rheumatology, Accepted Article.
Objective In APEX, guselkumab, which binds to the IL‐23p19 subunit and CD64 on IL‐23‐producing cells, demonstrated significant joint efficacy and inhibition of structural damage progression in participants with active and erosive PsA through Week (W)24; W48 findings are reported herein. Methods The APEX modified full analysis set included 1020 biologic‐
Christopher T. Ritchlin, Philip J. Mease, Laura C. Coates, Alexa P. Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Karissa Lozenski, Soumya D. Chakravarty, Proton Rahman, Désirée van der Heijde   +12 more
wiley   +1 more source

Unraveling the mystery of placebo effect in research and practice: An update. [PDF]

Perspect Clin Res
Mishra P, Bhargava S.
europepmc   +1 more source

MRI Quantification of Placebo Effect in Nonalcoholic Steatohepatitis Clinical Trials. [PDF]

Radiology, 2023
Nedrud MA, Chaudhry M, Middleton MS, Moylan CA, Lerebours R, Luo S, Farjat A, Guy C, Loomba R, Abdelmalek MF, Sirlin CB, Bashir MR.   +11 more
europepmc   +1 more source